Sleep disorders and their determinants in multiple system atrophy

I Ghorayeb, F Yekhlef, V Chrysostome, E Balestre, B Bioulac, F Tison

**SHORT REPORT**

**Sleep disorders and their determinants in multiple system atrophy**

I Ghorayeb, F Yekhlef, V Chrysostome, E Balestre, B Bioulac, F Tison

**OBJECTIVES:** To evaluate the incidence, types, determinants, and consequences of sleep disorders in patients with multiple system atrophy (MSA) and determine whether their characteristics are similar to those of patients with Parkinson’s disease (PD).

**Methods:** Information about sleep disorders was collected using a standardised questionnaire in an unselected group of 57 patients with MSA and in 62 patients with PD matched as a group for age, sex distribution, and disease duration.

**Results:** Seventy percent of patients with MSA complained of sleep disorders compared with 51% of patients with PD (p=0.03). The most commonly reported sleep disorders were sleep fragmentation (52.5%), vocalisation (60%), REM sleep behaviour disorder (47.5%), and nocturnal stridor (19%). Except for sleep fragmentation, the incidence of these disorders was significantly higher than in PD. Sleep problems tended to be associated with more severe motor symptoms, longer disease duration, depression, and longer duration of levodopa treatment. Half of patients with MSA with sleep disorders complained of daytime somnolence compared with 30% of patients with PD. Daytime somnolence was significantly associated with disease severity in MSA.

**Conclusion:** This study shows that sleep disorders are more common in patients with MSA than those with PD after the same duration of the disease, reflecting the more diffuse underlying pathological process in MSA.

**Sleep disorders are common in Parkinson’s disease (PD)**

S

**PATIENTS AND METHODS**

The University of Bordeaux 2 ethical committee approved the study. Fifty seven consecutive patients with MSA underwent a standardised face to face interview and examination protocol to fulfil MSA clinical diagnostic criteria for “possible” and “probable” MSA. Comparison was made with 62 outpatients with PD, who were recruited in parallel and matched as a group for sex, age, and disease duration.

Semiquantitative scales rating parkinsonism severity (Hoehn and Yahr stage, unified Parkinson’s disease rating scale (UPDRS-III) motor score, Schwab and England activity of daily living scale), self reported depressive symptoms (Center for Epidemiological Studies depression scale, CES-D), and mini mental state examination (MMSE) were administered. A structured interview collected data on disease history and medication. The standardised interview also assessed sleep problems (“yes” or “no” type of answer). If “yes”, they had to specify whether they had: 1, persistent initial insomnia (difficulty falling asleep within 30 minutes or more); 2, sleep fragmentation (more than two ≥30 minute nocturnal awakenings independently of the need to use the bathroom); 3, early awakening (undesirable early morning awakening with inability to fall asleep again); 4, daytime somnolence (undesirable and inappropriate dozing during waking hours). Data were collected with the assistance of the patient’s bed partner or an immediate household member for all the patients. Information was also sought on whether patients snores or had nocturnal motor symptoms (pain, cramps, nocturnal involuntary twisting movements, uncontrolled sudden jerks, and other abnormal nocturnal limb movements). Nocturnal stridor, described as a harsh or strained high pitched sound, and talking were investigated from the reports of the patients’ bed partners or caregivers’. Restless legs syndrome and rapid eye movement (REM) sleep behaviour disorder (RBD) were diagnosed according to the International classification of sleep disorders (ICSD) minimal diagnostic criteria. A Fisher’s exact test or a χ2 test was used when appropriate to compare the incidence of sleep disorders, types, determinants, and sex distribution in patients with MSA or PD. The mean age, disease duration and severity, duration of levodopa treatment, daily dose of levodopa, use of dopamine agonists and amantadine (“yes” or “no” type of answer), depressive symptoms, disability, and cognitive impairment scores were compared in patients with MSA or PD with and without sleep complaints using Student’s t test.

**RESULTS**

The mean age (67.3 (SD 8.5) years), sex distribution, and mean disease duration (5.75 (SD 3.36) years) of the 57 patients with MSA did not differ significantly from those of the 62 patients with PD (65.2 (SD 8.7) years and 7 (SD 4.37) years respectively). Thirty percent of patients with MSA were classified as MSA-C and 70% as MSA-P. Parkinsonism was significantly more severe in patients with MSA than in those with PD (mean Hoehn and Yahr score=3.23 (SD 1.36) t 2.18 (SD 0.76), p<0.0001; mean

**Abbreviations:** PD, Parkinson’s disease; MSA, multiple system atrophy; REM, rapid eye movement; RBD, REM sleep behaviour disorder; UPDRS, unified Parkinson’s disease rating scale; MMSE, mini mental state examination

www.jnnp.com
Sleep disorders in multiple system atrophy

Table 1  Nighttime problems in patients with Parkinson’s disease (PD) and multiple system atrophy (MSA)

<table>
<thead>
<tr>
<th>Patients (no)</th>
<th>SC</th>
<th>Insomnia</th>
<th>SF</th>
<th>EA</th>
<th>Vocalisation</th>
<th>RBD</th>
<th>RLS</th>
<th>Snoring</th>
<th>Stridor</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD (62)</td>
<td>51</td>
<td>19</td>
<td>38.7</td>
<td>42</td>
<td>13</td>
<td>9.7</td>
<td>3.2</td>
<td>56.7</td>
<td>0</td>
</tr>
<tr>
<td>MSA (57)</td>
<td>70*</td>
<td>20</td>
<td>52.5</td>
<td>32.5</td>
<td>60*</td>
<td>47.5*</td>
<td>12.5</td>
<td>72.5</td>
<td>19*</td>
</tr>
</tbody>
</table>

Values are percentages. *p<0.05 when compared with patients with PD.
SC, Sleep complaints; SF, sleep fragmentation; EA, early awakening; RBD, rapid eye movement (REM) sleep behaviour disorder; RLS, restless legs syndrome.

Table 2  Clinical characteristics of patients with Parkinson’s disease (PD) or multiple system atrophy (MSA) with and without sleep complaints

<table>
<thead>
<tr>
<th></th>
<th>PD patients with sleep complaints</th>
<th>PD patients without sleep complaints</th>
<th>MSA patients with sleep complaints</th>
<th>MSA patients without sleep complaints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>66.2 (7.9)</td>
<td>64.2 (9.7)</td>
<td>67.5 (7.8)</td>
<td>67 (10.2)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>8 (4.5)</td>
<td>6 (4.1)</td>
<td>6.2 [3.2]</td>
<td>4.7 (3.6)</td>
</tr>
<tr>
<td>Hoehn and Yahr score</td>
<td>2.34 (0.83)</td>
<td>1.98 (0.65)</td>
<td>3.32 (1.38)</td>
<td>3.03 (1.34)</td>
</tr>
<tr>
<td>UPDRS-III score</td>
<td>31.13 (13.11)</td>
<td>29.18 (13.87)</td>
<td>50.33 (19.64)</td>
<td>43.29 (17.17)</td>
</tr>
<tr>
<td>Schwab and England score</td>
<td>70.32 (22.13)</td>
<td>75.67 (15.69)</td>
<td>40.51 (24.7)</td>
<td>44.12 (26.71)</td>
</tr>
<tr>
<td>MMSE score</td>
<td>27.26 (2.64)</td>
<td>27.2 (2.07)</td>
<td>25.78 (3.79)</td>
<td>26.53 (2.89)</td>
</tr>
<tr>
<td>Autonomic failure (%)</td>
<td>41.94</td>
<td>27.59</td>
<td>95</td>
<td>82.35</td>
</tr>
<tr>
<td>CES-D score</td>
<td>14.04 (10.37)</td>
<td>11.9 (10.59)</td>
<td>21.06 (11.39)</td>
<td>18.71 (9.1)</td>
</tr>
<tr>
<td>Antidepressant use (%)</td>
<td>35.48</td>
<td>17.24</td>
<td>42.5</td>
<td>52.94</td>
</tr>
<tr>
<td>Daily levodopa (mg)</td>
<td>626.61 (367.24)</td>
<td>512.5 (349.82)</td>
<td>565.63</td>
<td>484.56</td>
</tr>
<tr>
<td>Duration of levodopa therapy (years)</td>
<td>6.8 (4.01)**</td>
<td>3.99 (3.49)</td>
<td>4 (3.66)</td>
<td>2.71 (3.34)</td>
</tr>
<tr>
<td>Dopamine agonist use (%)</td>
<td>74.2**</td>
<td>37.8</td>
<td>32.5</td>
<td>47.1</td>
</tr>
<tr>
<td>Amantadine use (%)</td>
<td>12.9</td>
<td>17.24</td>
<td>11.8</td>
<td>27.5</td>
</tr>
</tbody>
</table>

Values are presented as mean (SD) or percentages. *p<0.05 when compared with patients with PD.
**p<0.05 when compared with PD patients without sleep complaints.

UPDRS-III score=47.33 (SD 18.08) v 29.65 (SD 12.85), p<0.0001; mean Schwab and England score=41.6 (SD 25.14) v 73.06 (SD 19.13), p<0.0001. The mean daily levodopa dose was not significantly different in patients with MSA (752.7 (SD 362.1) mg) and those with PD (636.8 (SD 337) mg) nor was the mean duration of dopa treatment (4.4 (SD 3.82) years) v 5.8 (SD 3.97) years respectively. Some 37% of patients with MSA used dopaminergic agonists (bromocriptine, ropinirole, pergolide, piribedil, lisuride, apomorphine) vs 57% of patients with PD (p=0.02), and 23% of patients with MSA used amantadine v 15% of patients with PD.

Incidence and types of sleep problems
Table 1 shows the percentage of patients reporting nighttime disturbances in each group. A significantly higher percentage of patients with MSA complained of sleep disorders compared with patients with PD (70% v 51%, p=0.03). A significantly higher percentage of patients with MSA reported nighttime vocalisation and RBD than patients with PD (60% v 13%, p<0.0001; 47.5% v 9.7%, p=0.0006 respectively). Nocturnal stridor was reported only by patients with MSA (19%, p=0.0004).

Determinants of sleep disturbances
Table 2 shows the clinical characteristics of patients with MSA or PD, with and without sleep complaints. Patients with MSA or PD with sleep complaints tended to have longer disease duration, higher mean motor scores (UPDRS-III and Hoehn and Yahr stage), were more disabled with respect to activities of daily life, and reported more depressive symptoms than those without sleep complaints. Both groups of patients with sleep complaints tended to use higher daily levodopa doses, and patients with PD more often used dopamine agonists than those without sleep complaints. Amantadine use was not associated with more common sleep problems in either group. Unlike in patients with PD, duration of dopa treatment in patients with MSA was not significantly associated with sleep disorders.

Consequences of sleep disturbances
Use of hypnotic or antidepressant drugs was not significantly different in patients with MSA or PD. Half of patients with MSA compared with 30% of patients with PD admitted daytime somnolence and were significantly more severely disabled than those without daytime somnolence (mean UPDRS-III score=55.8 (SD 15.6) v 42.7 (SD 19.4), p=0.03; mean Hoehn and Yahr stage=3.84 (SD 0.88) v 2.8 (SD 1.6), p=0.02).

DISCUSSION
This is the first questionnaire based study of nighttime problems in a large unselected MSA population compared with patients with PD matched for age, sex, and disease duration. Although such studies may be limited by the accuracy of self reporting compared with polysomnographic studies, they make it possible to screen a broader and more representative sample of patients.

Overall, patients with MSA reported significantly more nighttime problems than patients with PD. In agreement with previous studies, difficulty in getting to sleep was similar in the two groups, a finding previously suggested to be mostly related to age. As already noted in patients with PD, sleep fragmentation and early awakening were also often reported.
by patients with MSA. The higher incidence of sleep fragmentation in patients with MSA suggests that the disease severity may favour this. Indeed, as for patients with PD, the mean UPDRS-III and Hoehn and Yahr scores for sleep disordered patients with MSA were higher than in patients with MSA without sleep problems.

Nocturnal vocalisation and RBD were more common in MSA, the former possibly being an early manifestation of RBD in patients with MSA. This may reflect the more extensive brainstem pathology in MSA. Nocturnal stridor occurred in 19% of patients with MSA, a result in keeping with that obtained by polysomnographic studies. Snoring also tended to be more common in patients with MSA. None of our patients with PD reported stridor. This suggests that snoring and stridor are not confused by the patients' bed partners. Although of potential interest, body mass index and neck circumference were not assessed, and there was no obvious clinical evidence of a weight bias between the two groups.

The role of dopaminergic agents in sleep disruption remains a matter of debate. On the one hand, the efficacy of dopa treatment and dopamine agonists in our patients with PD may partly explain the reduced occurrence of sleep disturbances compared with patients with MSA, but on the other, dopaminergic drugs may disrupt sleep and induce daytime somnolence. Accordingly, duration of dopa treatment, but not daily dose, and agonist use were the most significantly associated with sleep disorders in patients with PD but not in those with MSA.

Even if higher depressive symptom scores were associated with sleep problems in both groups of patients, no significant association was found with antidepressant use. However, these variables may be dependent as both depression and antidepressants may cause sleep disorders. More patients with MSA complained of daytime somnolence than patients with PD, arguing against the exclusive role of age, as proposed by others. Patients with MSA with daytime somnolence had significantly higher mean UPDRS-III and Hoehn and Yahr scores than those without, suggesting a probable role for degenerative process diffusion.

Conclusion

After the same duration of the disease, there was a higher incidence and variety of sleep disorders in patients with MSA than in those with PD. This paralleled the increasing severity of motor signs and the wider diffusion of the underlying degenerative process, which involves neuronal substrates for sleep organisation and maintenance, such as brainstem nuclei and/or basal ganglia.

ACKNOWLEDGEMENTS

This work was supported by a PHRC 1997 grant, Centre Hospitalier Universitaire de Bordeaux and CNRS (fellowship for I G).

Authors' affiliations

I Ghorayeb, B Bioulac, Service d'Explorations Fonctionnelles du Système Nerveux, Clinique du Sommeil, Hôpital Pellegrin, Place Amélie Rabotéon, 33076 Bordeaux cedex, France

F Yekhlef, V Chrysostome, F Tison, Service de Neurologie, Hôpital du Haut Lévêque, Avenue de Magellan, 33600 Pessac cedex, France

E Balestre, INSERM U-330 Biostatistiques et Epidémiologie, Université Bordeaux 2, 146, rue Léa-Saignat, 33076 Bordeaux cedex, France

Correspondence to: Professor F Tison, Service de Neurologie, Hôpital du Haut Lévêque, Avenue de Magellan, 33600 Pessac cedex, France; francois.tison@chu-bordeaux.fr

Received 9 July 2001
In revised form 11 October 2001
Accepted 13 December 2001

REFERENCES

Sleep disorders and their determinants in multiple system atrophy

I Ghorayeb, F Yekhlef, V Chrysostome, E Balestre, B Bioulac and F Tison

J Neurol Neurosurg Psychiatry 2002 72: 798-800
doi: 10.1136/jnnp.72.6.798

Updated information and services can be found at:
http://jnnp.bmj.com/content/72/6/798

These include:

References
This article cites 16 articles, 5 of which you can access for free at:
http://jnnp.bmj.com/content/72/6/798#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Sleep disorders (143)
Sleep disorders (neurology) (151)
Drugs: CNS (not psychiatric) (1945)
Movement disorders (other than Parkinsons) (766)
Parkinson's disease (690)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/